These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. [Therapeutic agents for disorders of bone and calcium metabolism. The calcimimetic cinacalcet HCl]. Nakanishi S; Fukagawa M Clin Calcium; 2007 Jan; 17(1):88-92. PubMed ID: 17211098 [TBL] [Abstract][Full Text] [Related]
3. Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism in stage 5 chronic kidney disease. Quarles LD Kidney Int Suppl; 2005 Jul; (96):S24-8. PubMed ID: 15954947 [TBL] [Abstract][Full Text] [Related]
5. Relationship between parathyroid calcium-sensing receptor expression and potency of the calcimimetic, cinacalcet, in suppressing parathyroid hormone secretion in an in vivo murine model of primary hyperparathyroidism. Kawata T; Imanishi Y; Kobayashi K; Kenko T; Wada M; Ishimura E; Miki T; Nagano N; Inaba M; Arnold A; Nishizawa Y Eur J Endocrinol; 2005 Oct; 153(4):587-94. PubMed ID: 16189180 [TBL] [Abstract][Full Text] [Related]
6. Hypercalcemia secondary to persistent hyperparathyroidism in kidney transplant patients: analysis after a year with cinacalcet. Guerra R; Auyanet I; Fernández EJ; Pérez MÁ; Bosch E; Ramírez A; Suria S; Checa MD J Nephrol; 2011; 24(1):78-82. PubMed ID: 20437396 [TBL] [Abstract][Full Text] [Related]
7. Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism caused by chronic kidney disease. Torres PU J Ren Nutr; 2006 Jul; 16(3):253-8. PubMed ID: 16825031 [TBL] [Abstract][Full Text] [Related]
8. Effect of paricalcitol and cinacalcet on serum phosphate, FGF-23, and bone in rats with chronic kidney disease. Finch JL; Tokumoto M; Nakamura H; Yao W; Shahnazari M; Lane N; Slatopolsky E Am J Physiol Renal Physiol; 2010 Jun; 298(6):F1315-22. PubMed ID: 20200094 [TBL] [Abstract][Full Text] [Related]
9. [Drugs inhibiting parathyroid hormone (PTH) secretion by control of the calcium receptor (calcimimetics)--effect on the set point of calcium-regulated PTH secretion]. Nagano N Clin Calcium; 2005 Jan; 15(1):71-8. PubMed ID: 15632475 [TBL] [Abstract][Full Text] [Related]
17. Calcimimetics: a remedy for all problems of excess parathyroid hormone activity in chronic kidney disease? Goodman WG Curr Opin Nephrol Hypertens; 2005 Jul; 14(4):355-60. PubMed ID: 15931004 [TBL] [Abstract][Full Text] [Related]
18. Treatment of severe hypercalcemia due to refractory hyperparathyroidism in renal transplant patients with the calcimimetic agent cinacalcet. Apostolou T; Damianou L; Kotsiev V; Drakopoulos S; Hadjiconstantinou V Clin Nephrol; 2006 May; 65(5):374-7. PubMed ID: 16724661 [TBL] [Abstract][Full Text] [Related]
19. Cinacalcet: An oral calcimimetic agent for the management of hyperparathyroidism. Dong BJ Clin Ther; 2005 Nov; 27(11):1725-51. PubMed ID: 16368445 [TBL] [Abstract][Full Text] [Related]
20. Treatment of secondary hyperparathyroidism in CKD patients with cinacalcet and/or vitamin D derivatives. Drüeke TB; Ritz E Clin J Am Soc Nephrol; 2009 Jan; 4(1):234-41. PubMed ID: 19056615 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]